Advanced search
Enter a research title, an expert name, a programme code such as ADSTEM, or a patent number such as 10-1172638. Results appear as cards with source links you can check yourself.
7 records for “exosome”
Each record states the study stage, institution and source link.
preclinical · 2024
EHL BIO (Korea)
The hospital's affiliated research centre states animal testing for patent application, listing neuropathic pain, cartilage regeneration, wound healing, hypertension, Alzheimer's disease, retinopathy, Parkinson's disease and diabetes as indications under study.
EHL BIO (other R&D page)phase1-2 · 2025
Multiple institutions (PubMed)
Some small studies report short-term increases in hair density, but preparations and endpoints vary widely and no large placebo-controlled trial exists.
PubMedpreclinical · 2025
Multiple institutions (PubMed)
Reduced pain behaviour and glial inflammation in animal models; not confirmed in humans.
PubMedpreclinical · 2024
Multiple institutions (PubMed)
Reduced vascular inflammation and target-organ fibrosis in animals; no human evidence of blood pressure or cardiovascular event reduction.
PubMedA patent evidences intellectual-property registration, not treatment efficacy.
No. 10-2021-0021026
Registered 17 Feb 2021
Cosmetic or pharmaceutical composition with urine-derived stem cell exosomes as the active ingredient.
EHL BIO patent pagePublished profiles contain only details checkable against public sources.
EHL BIO
Chief Executive Officer, EHLBIO Co., Ltd.
Direction of stem cell, immune cell and exosome therapeutics development
EHL BIO — CEO MessageEHL BIO
Stem cell therapeutics research and development team
ADSTEM (atopic dermatitis), KDSTEM (chronic kidney disease), RASTEM (rheumatoid arthritis), PDSTEM (Parkinson's disease) and adipose-derived exosome programmes
EHL BIO — Stem cell treatmentAn EHL doctor or scientist? Submit your real biography and licence for the register.
Submit expert profile